2017/12/12至今    重 庆 大 学    999全讯白菜网         副教授 / 硕导 / 博导

2014/08至2017/08  澳 门 大 学   健康科学学院   博 士

2013/07至2014/06  中国科学院广州生物医药与健康研究院

2010/08至2013/06  西 南 大 学   化学化工学院   硕 士

1. 肿瘤代谢关键靶点导向的抗肿瘤先导化合物设计及其作用机制研究

2. 靶向肿瘤代谢关键靶标选择性降解剂开发

3. 靶向肿瘤细胞线粒体的药物研发

4. 基于高通量筛选与计算机辅助设计的活性分子发现

5. 药物精准递送

1. 国家自然科学基金面上项目 (2025-01至2028-12, 项目负责人, 在研)

2. 国家自然科学基金青年基金 (2019-01至2021-12, 项目负责人, 结题)

3. 重庆市自然科学基金面上项目 (2024-07至2026-06, 项目负责人, 在研)

4. 重庆市自然科学基金面上项目 (2020-07至2023-06, 项目负责人, 结题)

5. 留学人员回国创业创新支持计划 (2022-01至2023-01, 项目负责人, 结题)

6. 企业横向 (2021-04至2021-12, 项目负责人, 结题)

7. 999策略白菜手机论坛科研启动经费 (2018-01-至今, 项目负责人, 在研)

8. 中央高校基本科研业务费专项 (2019-01-2020-01, 项目负责人，结题)

1. C. Li, M. Yang, Z. Cui, H. Yan, J. Ou, B. Xu*, Y. Wang*, Y. He, S.-L. Zhang*. Identification and structure-activity relationship optimization of dibromoacetophenones as novel mIDH1 inhibitors. Eur. J. Med. Chem. 2025, 299, 118050.

2. D. Luo, M. Zhang, Z. Liang, L. Gan*, Y. He, S.-L. Zhang*. Discovery and structure-activity relationship study of novel hydantoin-based inhibitors targeting mutant isocitrate dehydrogenase 1 (mIDH1). Eur. J. Med. Chem. 2025, 297, 117945.

3. D. Huang, M. Zhang, H. Yan, L. Mei, A. Yang, Y. He, K. Y. Tam*, S.-L. Zhang*. Unexpected discovery of a novel triphenylphosphonium alkylalcohol that triggers cancer cell death via mitophagy and ferroptosis. J. Med. Chem. 2025, 68, 11852-11874.

4. T. Li, R. Zhang, H. Gong, Z. Tang, X. Li, Z. Gong, M. Challa, C. Zou, S.-L. Zhang*, Jian Guo^*, Y. He^*. Synthesis and antibacterial evaluations of novel vancomycin analogues targeting bacteria membrane to combat Gram-negative infections. Eur. J. Med. Chem. 2025, 289, 117483.

5. T. Li, Z. Tang, R. Zhang, M. Challa, H. Gong, Z. Gong, S.-L. Zhang*, Jian Guo^*, Y. He^*. Targeted vancomycin delivery via in situ albumin conjugation and acid-triggered drug release for reduced nephrotoxicity. Eur. J. Med. Chem. 2025, 291, 117652.

6. Q. Li, J. Zhang, L. Dai, Y. Tan, W. Gao*, Y. Cheng*, S.-L. Zhang*, C.-H. Zhou*. Discovery of thiazolylcyanovinyl benzopyridone acids: Potential new generation antibacterial oxacins? Eur. J. Med. Chem. 2025, 297, 117901.

7. Q. Li, C. Zeng, Y. Chen, N. Ahmad, S.-L. Zhang*, C.-H. Zhou*. Natural coumarin-hybridized thiazolylbenzonitriles as new structural scaffolds to exert potentially multitargeting supramolecular antibacterial behavior. Chin. J. Chem. 2025, DOI: 10.1002/cjoc.70072.

8. X. Lu, S.-L. Zhang*, C.-H. Zhou*. Identification of hydroxyphenyl cyanovinyl thiazoles as new structural scaffold of potential antibacterial agents. Bioorg. Med. Chem. Lett. 2025, 124, 130258.

9. D. Liao, Y. Yang, S. Xiong, J. Feng, C. Zou, H. Peng, X. Yang, S.-L. Zhang*, Z.-P. Wang*, Y. He*, C. Huang*. Self-assembled GSH-responsive polycyclophosphazene loaded Honokiol nano-drug for enhanced cancer therapy. Colloids Surf. B 2025, 255, 114876.

10. P. Zhou, Y. Du, K. Ran, Z. Pan, M. Liu, H. Deng, J. Hu, Y. He, S.-L. Zhang*, J. Guo*. Modular synthesis of desferrioxamine B and its methotrexate conjugate as a selective trojan horse antibiotic that targets streptococcus pneumonia. Org. Lett. 2025, 27, 1719.

11. Y. Yang, Z. Zhao, X. Li, Y. Chen, L. Liu, S.-L. Zhang*, A. Yang*. Design and evaluation of peptide inhibitors targeting the dimerization of SARS-CoV-2 main protease. ChemBioChem. 2025, 26, e202400688.

12. W. Shan, S.-L. Zhang, Y. G. Assaraf, K. Y. Tam*. Combined inhibition of hexokinase 2 and pyruvate dehydrogenase surmounts SHP2 inhibitor resistance in non-small cell lung cancer with hybrid metabolic state harboring KRAS Q61H mutation. Biochim. Biophys. Acta Mol. Basis Dis. 2025, 1871, 167859.

Full publication list: https://www.researchgate.net/profile/Shao-Lin-Zhang